# A Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combination With Tislelizumab in Participants

Source: https://onco.cc/trials/nct05661955/  
OnCo record `nct05661955` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Tislelizumab in renal cell carcinoma and melanoma, run by BeiGene, active and no longer recruiting.

## Summary

A Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combination With Tislelizumab in Participants With Select Advanced Solid Tumors. is a phase 1/2 interventional study registered as NCT05661955 by BeiGene, with 113 participants enrolled, started 2023-01-09 and due to reach its primary completion in 2025-05-27. Interventions recorded: BGB-A445, Tislelizumab. Conditions listed: Urothelial Carcinoma, Renal Cell Carcinoma, Melanoma, Non-mucosal Melanoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05661955
- Phase: 1/2
- Setting: Phase 1b/2 Study Investigating the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of the Anti-OX40 Agonist Monoclonal Antibody BGB-A445 in Combination With the Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced or Metastatic Urothelial Carcinoma, Renal Cell Carcinoma, or Melanoma
- Sponsor: BeiGene
- Enrolled: 113

## Sources

- ClinicalTrials.gov NCT05661955: https://clinicaltrials.gov/study/NCT05661955

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/), [Renal cell carcinoma](https://onco.cc/cancers/rcc/)
- drugs: [Tislelizumab](https://onco.cc/drugs/tislelizumab/)
- companies: [BeOne Medicines (formerly BeiGene)](https://onco.cc/companies/beone/)

---
JSON: https://onco.cc/api/v1/entities/nct05661955.json